{
  "meta": {
    "title": "17_Platelet_Disorders",
    "url": "https://brainandscalpel.vercel.app/17-platelet-disorders-4022bfb3.html",
    "scrapedAt": "2025-11-30T06:59:18.395Z"
  },
  "questions": [
    {
      "id": 97823,
      "choices": [
        {
          "id": 297379,
          "text": "Von Willebrand disease"
        },
        {
          "id": 297380,
          "text": "Hemophilia A"
        },
        {
          "id": 297381,
          "text": "DIC"
        },
        {
          "id": 297382,
          "text": "Both A & C"
        }
      ],
      "text": "Bleeding time increased in which of the following conditions?",
      "unique_key": "Q3657314",
      "question_audio": null,
      "question_video": null,
      "map_id": 34312675,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Both A & C Option C- coagulation factor defect Bleeding time is a laboratory test to assess platelet function and the body’s ability to form a clot. The test involves making a puncture wound in a superficial area of the skin and monitoring the time needed for bleeding to stop (ie, bleeding site turns “glassy”).",
      "correct_choice_id": 297382,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/70408761700578654/70408761700578654.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/70408761700578654/70408761700578654.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97824,
      "choices": [
        {
          "id": 297383,
          "text": "It is due to defect in platelet adhesion"
        },
        {
          "id": 297384,
          "text": "It is due to defect in platelet aggregation"
        },
        {
          "id": 297385,
          "text": "It is due to defect in platelet receptor GpIb-IX"
        },
        {
          "id": 297386,
          "text": "Both a and c"
        }
      ],
      "text": "Which of the following is true regarding Bernard-Soulier syndrome?",
      "unique_key": "Q3237640",
      "question_audio": null,
      "question_video": null,
      "map_id": 34393100,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Both A and C Bernard-Soulier syndrome illustrates the consequences of defective adhesion of platelets to subendothelial matrix. Bernard-Soulier syndrome is caused by an inherited deficiency of the platelet membrane glyco protein complex Ib-IX. This glycoprotein is a receptor for vWF and is essential for normal platelet adhesion to the subendothelial extracellular matrix. Affected patients have a variable, often severe, bleeding tendency",
      "correct_choice_id": 297386,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/76759251700578671/76759251700578671.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/76759251700578671/76759251700578671.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97825,
      "choices": [
        {
          "id": 297387,
          "text": "Extrinsic"
        },
        {
          "id": 297388,
          "text": "Intrinsic"
        },
        {
          "id": 297389,
          "text": "Fibrinolytic"
        },
        {
          "id": 297390,
          "text": "Common"
        }
      ],
      "text": "In PT test, the addition of Ca2+ & tissue thromboplastin activates which pathway?",
      "unique_key": "Q9408373",
      "question_audio": null,
      "question_video": null,
      "map_id": 34749269,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Extrinsic pathway. The addition of calcium ions (Ca2+) and tissue thromboplastin (also called tissue factor or Factor III) to plasma specifically activates the extrinsic pathway of the coagulation cascade. Tissue thromboplastin is a key component in this pathway as it forms a complex with Factor VII and Ca2+ (TF-FVIIa complex). This complex then activates Factor X, which is part of the common pathway, initiating the clotting process. The extrinsic pathway is essential for initiating coagulation in response to vascular injury and serves as a rapid response mechanism compared to the intrinsic pathway. Reasons for Incorrect Options: B. Intrinsic pathway: The intrinsic pathway is activated by damage to the endothelial surface or exposure of blood to negatively charged surfaces (e.g., collagen, subendothelial structures). It involves Factors XII, XI, IX, and VIII. Tissue thromboplastin does not play a role in the activation of this pathway, making this option incorrect. C. Fibrinolytic pathway: The fibrinolytic pathway is responsible for breaking down clots and involves plasminogen activation to plasmin. It is not involved in the formation of clots and is unrelated to the action of Ca2+ and tissue thromboplastin, so this is not correct. D. Common pathway: While the extrinsic pathway feeds into the common pathway by activating Factor X, the question specifically asks about the pathway activated directly by Ca2+ and tissue thromboplastin. The common pathway involves the downstream steps, including the conversion of prothrombin to thrombin and fibrinogen to fibrin, but it is not the pathway primarily activated in this context.",
      "correct_choice_id": 297387,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/22930591700578695/22930591700578695.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/22930591700578695/22930591700578695.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97826,
      "choices": [
        {
          "id": 297391,
          "text": "Factor VIII C deficiency"
        },
        {
          "id": 297392,
          "text": "BT prolonged"
        },
        {
          "id": 297393,
          "text": "Normal ristocetin test"
        },
        {
          "id": 297394,
          "text": "Defective adhesion"
        }
      ],
      "text": "Von Willebrand disease, all are true except-",
      "unique_key": "Q6781916",
      "question_audio": null,
      "question_video": null,
      "map_id": 34329678,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Normal ristocetin test Patients with von Willebrand disease have defects in platelet function despite a normal platelet count. The plasma level of active vWF, measured as the ristocetin cofactor activity, is reduced. Because vWF stabilizes factor VIII, a deficiency of vWF gives rise to a secondary decrease in factor VIII levels. This may be reflected by a prolongation of the PTT in von Willebrand disease types 1 and 3.However, except in rare type 3 patients, adverse complications typical of severe factor VIII deficiency, such as bleeding into the joints, are not seen. Even within families in which a single defective vWF allele is segregating, wide variability in clinical expression is common. This is due in part to modifying genes that influence circulating levels of vWF, which show a wide range in normal populations. Persons with von Willebrand disease facing hemostatic challenges (dental work, surgery) can be treated with desmopressin, which stimulates vWF release, or with infusions of plasma concentrates containing factor VIII and vWF.",
      "correct_choice_id": 297393,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/76127801700578766/76127801700578766.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/76127801700578766/76127801700578766.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97827,
      "choices": [
        {
          "id": 297395,
          "text": "Platelet aggregation"
        },
        {
          "id": 297396,
          "text": "Platelet adhesion"
        },
        {
          "id": 297397,
          "text": "Decreased ADP release"
        },
        {
          "id": 297398,
          "text": "Disordered platelet secretion"
        }
      ],
      "text": "In Glanzmann thromboasthenia there is a defect in-",
      "unique_key": "Q5938633",
      "question_audio": null,
      "question_video": null,
      "map_id": 34145770,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Platelet aggregation Bleeding due to defective platelet ag- gregation is exemplified by Glanzmann thrombasthenia, which is also trans- mitted as an autosomal recessive trait. Thrombasthenic platelets fail to aggre- gate in response to adenosine diphos- phate (ADP), collagen, epinephrine, or thrombin because of deficiency or dys- function of glycoprotein IIbIIIa, an integ- rin that participates in “bridge formation” between platelets by binding fibrinogen. The associated bleeding tendency is of- ten severe",
      "correct_choice_id": 297395,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/11072181700578813/11072181700578813.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/11072181700578813/11072181700578813.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97828,
      "choices": [
        {
          "id": 297399,
          "text": "Factor X deficiency"
        },
        {
          "id": 297400,
          "text": "Glanzmann thrombasthenia"
        },
        {
          "id": 297401,
          "text": "Von Willebrand disease"
        },
        {
          "id": 297402,
          "text": "Bernard-Soulier disease"
        }
      ],
      "text": "A newborn baby presented with profuse bleeding from the umbilical stump after birth. Rest of the Examination and PT, APTT are within normal limits. Most of probable diagnosis is-",
      "unique_key": "Q6124292",
      "question_audio": null,
      "question_video": null,
      "map_id": 34345267,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Glanzmann thrombasthenia. Glanzmann thrombasthenia is a rare inherited disorder of platelet function caused by a deficiency or dysfunction of glycoprotein IIb/IIIa (GPIIb/IIIa) receptors on platelets. These receptors are essential for platelet aggregation, as they mediate binding to fibrinogen, enabling platelet clumping to form a stable clot. Despite normal platelet count and morphology, affected individuals present with mucocutaneous bleeding, including profuse bleeding from sites like the umbilical stump in newborns. Since PT (prothrombin time) and APTT (activated partial thromboplastin time) measure coagulation factor activity and are normal in platelet function disorders, they do not help identify this condition, further pointing to a platelet dysfunction diagnosis like Glanzmann thrombasthenia. Reasons for Incorrect Options: A. Factor X deficiency: Factor X is a clotting factor involved in the common coagulation pathway, and its deficiency results in prolonged PT and APTT, as it disrupts the coagulation cascade. In this case, both PT and APTT are normal, ruling out Factor X deficiency. Moreover, severe bleeding from the umbilical stump is not typically the sole presentation of Factor X deficiency. C. Von Willebrand disease (VWD): VWD is a common bleeding disorder caused by a deficiency or dysfunction of von Willebrand factor (vWF), which is essential for platelet adhesion and stabilizing Factor VIII. While VWD can cause prolonged bleeding, it often leads to prolonged APTT in severe cases and typically manifests later in life with mucosal or menstrual bleeding. Normal PT and APTT and profuse umbilical stump bleeding make this diagnosis less likely. D. Bernard-Soulier disease: Bernard-Soulier disease is a platelet adhesion disorder caused by a deficiency of the glycoprotein Ib/IX/V complex, which binds vWF to subendothelial collagen. While it may cause bleeding, it is less likely to present as profuse bleeding from the umbilical stump. Additionally, it is often associated with thrombocytopenia and large platelets, which are not indicated in the question. Normal PT and APTT also make this diagnosis less probable.",
      "correct_choice_id": 297400,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/44002791700578826/44002791700578826.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/44002791700578826/44002791700578826.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97829,
      "choices": [
        {
          "id": 297403,
          "text": "Thrombocytopenia"
        },
        {
          "id": 297404,
          "text": "Increased PT"
        },
        {
          "id": 297405,
          "text": "Hyperfibrinogenemia"
        },
        {
          "id": 297406,
          "text": "Increased FDP"
        }
      ],
      "text": "What is not associated with DIC-",
      "unique_key": "Q9034290",
      "question_audio": null,
      "question_video": null,
      "map_id": 34533198,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Hyperfibrinogenemia Disseminated intravascular coagulation (DIC) is a pathological process characterized by widespread activation of the coagulation cascade, leading to the consumption of clotting factors and platelets and secondary activation of fibrinolysis. In DIC, fibrinogen is consumed in the formation of fibrin clots, leading to hypofibrinogenemia rather than hyperfibrinogenemia. This consumption contributes to the bleeding tendency observed in DIC patients. Therefore, hyperfibrinogenemia (increased levels of fibrinogen) is not associated with DIC and makes this option incorrect. Reasons for Incorrect Options: A. Thrombocytopenia: Thrombocytopenia is a hallmark of DIC. Platelets are consumed in the formation of microthrombi in the small blood vessels, leading to a decreased platelet count. This is a common finding in DIC and supports the diagnosis. B. Increased PT: In DIC, the prothrombin time (PT) is prolonged due to the consumption of clotting factors like Factor V and Factor VIII. This is indicative of the coagulation cascade's dysfunction and is a classic laboratory finding in DIC, making this option correct. D. Increased FDP: Fibrin degradation products (FDPs), including D-dimers, are elevated in DIC due to the breakdown of fibrin clots by fibrinolysis. This is a key diagnostic marker of DIC, reflecting the increased fibrin turnover and degradation. Elevated FDP levels are characteristic of DIC and reinforce the diagnosis.",
      "correct_choice_id": 297405,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/40741031700578859/40741031700578859.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/40741031700578859/40741031700578859.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97830,
      "choices": [
        {
          "id": 297407,
          "text": "Vasoconstriction"
        },
        {
          "id": 297408,
          "text": "Platelet adhesion"
        },
        {
          "id": 297409,
          "text": "Platelet aggregation"
        },
        {
          "id": 297410,
          "text": "Vasodilatation"
        }
      ],
      "text": "Earliest event of vascular trauma is?",
      "unique_key": "Q8406982",
      "question_audio": null,
      "question_video": null,
      "map_id": 34153269,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Vasoconstriction The earliest event following vascular trauma is vasoconstriction. When blood vessels are injured, the immediate response is the constriction of the vessel at the site of injury. This is mediated by reflex neural mechanisms and the release of local factors such as endothelin from endothelial cells. Vasoconstriction reduces blood flow to the damaged area, minimizing blood loss and allowing time for the subsequent processes of hemostasis, such as platelet adhesion and clot formation, to occur effectively. Reasons for Incorrect Options: B. Platelet adhesion: Platelet adhesion occurs shortly after vasoconstriction. It involves platelets binding to exposed subendothelial structures, such as collagen, via von Willebrand factor (vWF). Although critical for initiating the platelet plug, it is a secondary event that follows vasoconstriction, making this option incorrect. C. Platelet aggregation: Platelet aggregation refers to the process where platelets adhere to one another to form a stable platelet plug. This step depends on platelet adhesion and the activation of glycoprotein IIb/IIIa receptors. Since aggregation occurs later in the hemostatic process, it cannot be the earliest event, making this option incorrect. D. Vasodilatation: Vasodilatation is the widening of blood vessels and is generally associated with normal tissue perfusion or inflammation rather than hemostasis. It is not part of the immediate response to vascular injury, and instead, the opposite—vasoconstriction—occurs in the initial stage. Hence, this option is incorrect",
      "correct_choice_id": 297407,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/33231091700578911/33231091700578911.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/33231091700578911/33231091700578911.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97831,
      "choices": [
        {
          "id": 297411,
          "text": "Alpha"
        },
        {
          "id": 297412,
          "text": "Beta"
        },
        {
          "id": 297413,
          "text": "Delta"
        },
        {
          "id": 297414,
          "text": "None"
        }
      ],
      "text": "PDGF is present in which granules of platelets?",
      "unique_key": "Q7246477",
      "question_audio": null,
      "question_video": null,
      "map_id": 34302547,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Alpha Platelet-derived growth factor (PDGF) is stored in the alpha granules of platelets. Alpha granules are the most abundant granules in platelets and contain various proteins essential for clot formation and tissue repair, including fibrinogen, von Willebrand factor (vWF), and growth factors like PDGF. Upon platelet activation, alpha granules release their contents into the extracellular space to facilitate wound healing and tissue regeneration. PDGF, specifically, plays a key role in promoting the proliferation and migration of smooth muscle cells and fibroblasts, which are critical for tissue repair. Reasons for Incorrect Options: B. Beta: There are no \"beta granules\" in platelets. This term does not refer to any known type of platelet granule, making this option incorrect. C. Delta: Delta granules, also known as dense granules, contain small molecules like serotonin, ADP, ATP, and calcium ions. These molecules are involved in platelet aggregation and vasoconstriction, but they do not store PDGF. Thus, this option is incorrect. D. None: This option implies that PDGF is not present in any platelet granule, which is incorrect. PDGF is specifically stored in the alpha granules of platelets, making this option incorrect as well.",
      "correct_choice_id": 297411,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/5444661700578988/5444661700578988.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/5444661700578988/5444661700578988.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97832,
      "choices": [
        {
          "id": 297415,
          "text": "Type 1&3 are associated withquantitative defects in vWF"
        },
        {
          "id": 297416,
          "text": "Normal platelet count"
        },
        {
          "id": 297417,
          "text": "Desmopressin stimulates release of VWF"
        },
        {
          "id": 297418,
          "text": "All of the above"
        }
      ],
      "text": "Which of the following is true regarding Von willebrand disease?",
      "unique_key": "Q2286994",
      "question_audio": null,
      "question_video": null,
      "map_id": 34235960,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All of the above. Von Willebrand disease (VWD) is the most common inherited bleeding disorder and is caused by a deficiency or dysfunction of von Willebrand factor (vWF). Each of the statements provided is accurate regarding VWD: Type 1 and Type 3 are associated with quantitative defects in vWF. In Type 1, there is a partial quantitative deficiency of vWF, while in Type 3, there is a near-complete or complete absence of vWF, making it the most severe form. Both types are quantitative defects, in contrast to Type 2, which involves qualitative abnormalities of vWF function. Normal platelet count: VWD typically presents with normal platelet count since it primarily affects platelet adhesion and not platelet production or survival. Despite this, the interaction between platelets and the vessel wall is impaired due to vWF deficiency or dysfunction. Desmopressin stimulates release of vWF: Desmopressin (DDAVP) is a synthetic analog of vasopressin that stimulates the release of vWF from endothelial cells, specifically from Weibel-Palade bodies. It is commonly used to treat mild forms of VWD (Type 1) and can transiently increase vWF levels in the plasma. Because all the statements are true, the correct choice is D. All of the above. Reasons for Incorrect Options: A. Type 1 & 3 are associated with quantitative defects in vWF: This is correct but does not encompass the full scope of the question, as it does not address other features of VWD. B. Normal platelet count: This is true for VWD but only represents one aspect of the condition. C. Desmopressin stimulates release of vWF: This statement is accurate but focuses solely on the therapeutic aspect of VWD management. Since all the individual statements are true and collectively describe key aspects of VWD, the most comprehensive answer is D. All of the above.",
      "correct_choice_id": 297418,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/27781561700579005/27781561700579005.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/27781561700579005/27781561700579005.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97833,
      "choices": [
        {
          "id": 297419,
          "text": "Hemoptysis"
        },
        {
          "id": 297420,
          "text": "Hemarthrosis"
        },
        {
          "id": 297421,
          "text": "Hematemesis"
        },
        {
          "id": 297422,
          "text": "Mucosal bleeding"
        }
      ],
      "text": "Which of the following is the most common manifestation of haemophilia?",
      "unique_key": "Q6645013",
      "question_audio": null,
      "question_video": null,
      "map_id": 34532422,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Hemarthrosis Hemarthrosis, or bleeding into the joints, is the most common manifestation of hemophilia, particularly in severe cases. It is caused by the deficiency of clotting factors (Factor VIII in hemophilia A or Factor IX in hemophilia B), leading to prolonged bleeding after minor trauma. Weight-bearing joints like the knees, ankles, and elbows are most commonly affected. Recurrent hemarthrosis can result in chronic joint damage, pain, and deformities (hemophilic arthropathy). The prominence of hemarthrosis is a hallmark feature distinguishing hemophilia from other bleeding disorders. Reasons for Incorrect Options: A. Hemoptysis: Hemoptysis (coughing up blood) is not a typical manifestation of hemophilia. While bleeding can occur in various sites, respiratory tract bleeding is uncommon in hemophilia and usually associated with other conditions such as infections, lung diseases, or trauma, making this option incorrect. C. Hematemesis: Hematemesis (vomiting blood) is not a common feature of hemophilia. It is more typically associated with gastrointestinal conditions such as peptic ulcers or variceal bleeding. Gastrointestinal bleeding can occur in hemophilia but is not the most frequent manifestation, making this option less likely. D. Mucosal bleeding: Mucosal bleeding (e.g., epistaxis, gum bleeding) is more commonly seen in platelet dysfunction or von Willebrand disease. While mucosal bleeding can occasionally occur in hemophilia, it is not the most characteristic or frequent manifestation of the condition, making this option incorrect.",
      "correct_choice_id": 297420,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/77727921700579030/77727921700579030.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/77727921700579030/77727921700579030.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97834,
      "choices": [
        {
          "id": 297423,
          "text": "F XI"
        },
        {
          "id": 297424,
          "text": "F X"
        },
        {
          "id": 297425,
          "text": "F III"
        },
        {
          "id": 297426,
          "text": "F XIII"
        }
      ],
      "text": "Which coagulation factor is not in circulating form in blood?",
      "unique_key": "Q5971294",
      "question_audio": null,
      "question_video": null,
      "map_id": 34634567,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Factor III Factor III (tissue factor or thromboplastin) is not found in circulating form in the blood. It is a membrane-bound glycoprotein expressed on the surface of subendothelial tissues and certain cells, such as fibroblasts and smooth muscle cells. Tissue factor plays a critical role in the initiation of the extrinsic pathway of coagulation. It is exposed to circulating blood only when there is vascular injury, triggering the coagulation cascade by binding to Factor VII. Since it is not a soluble or circulating factor, it is distinct from other coagulation factors. Reasons for Incorrect Options: A. Factor XI: Factor XI is a circulating coagulation factor present in plasma in its inactive form. It is activated to Factor XIa as part of the intrinsic pathway of coagulation. Since it exists in a circulating form, this option is incorrect. B. Factor X: Factor X is a key coagulation factor that circulates in the blood in its inactive form. It becomes activated to Factor Xa in both the intrinsic and extrinsic pathways, playing a pivotal role in the common pathway. As it is a circulating factor, this option is incorrect. D. Factor XIII: Factor XIII is a circulating coagulation factor, present in plasma in an inactive form. It becomes activated by thrombin to Factor XIIIa and is crucial for stabilizing the fibrin clot by cross-linking fibrin strands. Since it circulates in the blood, this option is incorrect.",
      "correct_choice_id": 297425,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/13431191700579046/13431191700579046.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/13431191700579046/13431191700579046.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97835,
      "choices": [
        {
          "id": 297427,
          "text": "Endothelium"
        },
        {
          "id": 297428,
          "text": "RBC"
        },
        {
          "id": 297429,
          "text": "Platelets"
        },
        {
          "id": 297430,
          "text": "WBC"
        }
      ],
      "text": "Endotoxin first damages?",
      "unique_key": "Q5163853",
      "question_audio": null,
      "question_video": null,
      "map_id": 34503749,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Endothelium Endotoxins, which are lipopolysaccharides (LPS) present in the outer membrane of Gram-negative bacteria, primarily damage the endothelium as their first target. Upon release, endotoxins bind to receptors like Toll-like receptor 4 (TLR4) on endothelial cells, triggering the release of inflammatory cytokines, such as TNF-α, IL-1, and IL-6. This leads to endothelial cell activation and damage, increased vascular permeability, and the promotion of a pro-coagulant state. The resulting endothelial dysfunction plays a central role in the pathogenesis of conditions like sepsis and disseminated intravascular coagulation (DIC), making the endothelium the primary site of endotoxin-induced damage. Reasons for Incorrect Options: B. RBC: Endotoxins do not directly target or damage red blood cells (RBCs). While hemolysis can occur in severe systemic inflammatory responses due to mechanical or oxidative stress, this is a secondary effect rather than a direct result of endotoxin action. Thus, this option is incorrect. C. Platelets: Endotoxins can indirectly affect platelets by activating the coagulation cascade and causing platelet consumption, especially in DIC. However, platelets are not the first targets of endotoxins. The damage to the endothelium precedes platelet activation and consumption, making this option incorrect. D. WBC: While endotoxins activate white blood cells (WBCs) by binding to receptors like CD14 and TLR4, they do not directly damage them. WBC activation results in the release of pro-inflammatory cytokines and reactive oxygen species, contributing to tissue damage, but this is not a direct effect on the WBCs themselves. Therefore, this option is incorrect.",
      "correct_choice_id": 297427,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28130281700579090/28130281700579090.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/28130281700579090/28130281700579090.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97836,
      "choices": [
        {
          "id": 297431,
          "text": "CT"
        },
        {
          "id": 297432,
          "text": "aPTT"
        },
        {
          "id": 297433,
          "text": "TT"
        },
        {
          "id": 297434,
          "text": "Prothrombin time"
        }
      ],
      "text": "Which of the following measures the intrinsic pathway",
      "unique_key": "Q2333092",
      "question_audio": null,
      "question_video": null,
      "map_id": 34772891,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) aPTT (Activated Partial Thromboplastin Time). aPTT is a test used to measure the intrinsic pathway of coagulation. It assesses the function of several coagulation factors involved in the intrinsic pathway, including Factor XII, XI, IX, VIII, as well as Factor X, V, prothrombin, and fibrinogen. The aPTT test evaluates how long it takes for blood to clot after the addition of an activator (such as kaolin) and calcium, which activates the intrinsic pathway. An abnormal aPTT can indicate a deficiency or dysfunction in any of the intrinsic pathway factors. Reasons for Incorrect Options: A. CT (Clotting time): Clotting time is a general test for the overall time it takes for a blood sample to clot but does not specifically measure the intrinsic or extrinsic pathways of coagulation. It is not a precise test for the intrinsic pathway, making this option incorrect. C. TT (Thrombin time): The thrombin time measures the final step in the coagulation cascade, where fibrinogen is converted to fibrin by thrombin. It does not assess the intrinsic pathway but instead evaluates the functionality of fibrinogen and the presence of thrombin inhibitors. Thus, this option is incorrect. D. Prothrombin time (PT): PT measures the extrinsic pathway of coagulation, specifically evaluating the activity of Factor VII and the common pathway (Factor X, V, prothrombin, and fibrinogen). It is not used to assess the intrinsic pathway, making this option incorrect.",
      "correct_choice_id": 297432,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/30135341700579103/30135341700579103.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/30135341700579103/30135341700579103.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97837,
      "choices": [
        {
          "id": 297435,
          "text": "Defect in extrinsic pathway"
        },
        {
          "id": 297436,
          "text": "Defect in intrinsic pathway"
        },
        {
          "id": 297437,
          "text": "Defect in common pathway"
        },
        {
          "id": 297438,
          "text": "Defect in platelet function"
        }
      ],
      "text": "An 11 years old boy has elevated prothrombin and activated partial prothrombin time. What is the most likely defect?",
      "unique_key": "Q2444985",
      "question_audio": null,
      "question_video": null,
      "map_id": 34274611,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Defect in the common pathway The common pathway of coagulation involves Factors X, V, prothrombin (Factor II), and fibrinogen. Since both prothrombin time (PT) and activated partial thromboplastin time (aPTT) are elevated in this case, the defect likely lies in one of the factors common to both pathways, such as Factor X, Factor V, or prothrombin. When there is a defect in any of these factors, both PT and aPTT will be prolonged because they are involved in the final steps of both the intrinsic and extrinsic coagulation cascades. Therefore, a defect in the common pathway is the most likely cause of the elevated PT and aPTT. Reasons for Incorrect Options: A. Defect in the extrinsic pathway: The extrinsic pathway involves Factor VII and tissue factor (Factor III), and its deficiency typically prolongs only the PT, not the aPTT. The aPTT would remain normal unless there is a concurrent issue with the intrinsic or common pathway. Since both PT and aPTT are elevated in this case, a defect in the extrinsic pathway is unlikely. B. Defect in the intrinsic pathway: The intrinsic pathway involves Factors XII, XI, IX, and VIII. A defect in any of these factors would primarily affect the aPTT and would not typically prolong the PT unless there is a secondary involvement of the common pathway. Since both PT and aPTT are elevated, a defect confined to the intrinsic pathway is less likely. D. Defect in platelet function: Platelet function defects usually lead to bleeding disorders that present with normal PT and aPTT. Platelet function abnormalities manifest as issues with platelet aggregation, which do not affect the clotting times measured by PT and aPTT. Therefore, a defect in platelet function is unlikely to explain the elevated PT and aPTT in this case.",
      "correct_choice_id": 297437,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48049591700579117/48049591700579117.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48049591700579117/48049591700579117.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97838,
      "choices": [
        {
          "id": 297439,
          "text": "Increased risk of deep vein thrombosis"
        },
        {
          "id": 297440,
          "text": "Factor V becomes resistant to cleavage by protein C"
        },
        {
          "id": 297441,
          "text": "Glutamine to Arginine substitution at 506"
        },
        {
          "id": 297442,
          "text": "All of the above"
        }
      ],
      "text": "Which of the following is true regarding Factor V Leiden mutation?",
      "unique_key": "Q1875413",
      "question_audio": null,
      "question_video": null,
      "map_id": 34792341,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All of the above. Factor V Leiden mutation is a genetic mutation in which there is a point mutation in the Factor V gene, specifically at position 506, where glutamine is substituted with arginine. This mutation causes Factor V to become resistant to cleavage by activated protein C (APC), which normally downregulates clotting. As a result, there is an increased tendency for clot formation, particularly deep vein thrombosis (DVT). The resistance to APC leads to a hypercoagulable state, increasing the risk of thrombotic events like DVT and pulmonary embolism. Therefore, all the statements in the options are correct. Reasons for Incorrect Options: Since D. All of the above is the correct answer and all individual components are true, there are no incorrect responses in this question. Each option describes a valid characteristic of the Factor V Leiden mutation: A. Increased risk of deep vein thrombosis: This is true, as the mutation leads to an increased risk of venous thromboembolism, particularly DVT. B. Factor V becomes resistant to cleavage by protein C: This is the hallmark of the mutation, leading to reduced anticoagulant activity of protein C and a tendency for clot formation. C. Glutamine to Arginine substitution at 506: This describes the specific molecular change that causes Factor V Leiden mutation, further confirming the validity of the other options.",
      "correct_choice_id": 297442,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/11457551700579133/11457551700579133.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/11457551700579133/11457551700579133.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97839,
      "choices": [
        {
          "id": 297443,
          "text": "Delta granules of platelets"
        },
        {
          "id": 297444,
          "text": "Weibel-Palade bodies"
        },
        {
          "id": 297445,
          "text": "Kupffer cells"
        },
        {
          "id": 297446,
          "text": "Merkel cells"
        }
      ],
      "text": "Where can Von Willebrand factor (VWF) be found in the body?",
      "unique_key": "Q8501514",
      "question_audio": null,
      "question_video": null,
      "map_id": 34064524,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Weibel-Palade bodies. Von Willebrand factor (vWF) is primarily stored in Weibel-Palade bodies, which are specialized storage granules found in endothelial cells. vWF plays a key role in platelet adhesion to the damaged vessel wall and in stabilizing Factor VIII, a critical factor in the coagulation cascade. When vascular injury occurs, vWF is released from the Weibel-Palade bodies into the bloodstream, facilitating hemostasis by promoting platelet aggregation and clot formation. Reasons for Incorrect Options: A. Delta granules of platelets: While platelets store a variety of substances in their granules, including ADP, serotonin, and calcium, vWF is not typically stored in the delta granules of platelets. vWF is produced and stored in endothelial cells, specifically within the Weibel-Palade bodies, not platelets. C. Kupffer cells: Kupffer cells are specialized macrophages in the liver, primarily involved in the filtration of blood and removal of pathogens. They do not store Von Willebrand factor. vWF is not stored or produced in Kupffer cells, making this option incorrect. D. Merkel cells: Merkel cells are specialized mechanoreceptor cells found in the skin, particularly in the epidermis. They are not involved in the storage or production of Von Willebrand factor, so this option is incorrect.",
      "correct_choice_id": 297444,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/41824691700579143/41824691700579143.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/41824691700579143/41824691700579143.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97840,
      "choices": [
        {
          "id": 297447,
          "text": "Hemophilia A"
        },
        {
          "id": 297448,
          "text": "Hemophilia B"
        },
        {
          "id": 297449,
          "text": "Von Willebrand disease"
        },
        {
          "id": 297450,
          "text": "Factor XI deficiency"
        }
      ],
      "text": "What is the most common inherited bleeding disorder?",
      "unique_key": "Q6219499",
      "question_audio": null,
      "question_video": null,
      "map_id": 34774232,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Von Willebrand disease Von Willebrand disease (VWD) is the most common inherited bleeding disorder, affecting both males and females equally. It is caused by a deficiency or dysfunction of von Willebrand factor (vWF), a protein crucial for platelet adhesion and clot formation. VWD can be classified into three types based on the severity and nature of the defect in vWF. Due to its widespread prevalence and the fact that it can be inherited in an autosomal dominant fashion, it is the most common bleeding disorder. Reasons for Incorrect Options: A. Hemophilia A: Hemophilia A, caused by a deficiency of Factor VIII, is a serious inherited bleeding disorder but is much less common than Von Willebrand disease. Hemophilia A primarily affects males, as it is X-linked recessive. Therefore, although hemophilia A is one of the more well-known bleeding disorders, it is not the most common inherited bleeding disorder. B. Hemophilia B: Hemophilia B, also known as Christmas disease, is caused by a deficiency of Factor IX and, like hemophilia A, is an X-linked recessive disorder. It is less common than hemophilia A and, by extension, less common than Von Willebrand disease. This makes it an incorrect answer. D. Factor XI deficiency: Factor XI deficiency is a rare inherited bleeding disorder that causes mild to moderate bleeding tendencies. While it can be inherited in an autosomal dominant manner, it is far less common than Von Willebrand disease. This option is incorrect because Factor XI deficiency is not the most common inherited bleeding disorder.",
      "correct_choice_id": 297449,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/42829411700579153/42829411700579153.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/42829411700579153/42829411700579153.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97841,
      "choices": [
        {
          "id": 297451,
          "text": "II, VII, IX, X"
        },
        {
          "id": 297452,
          "text": "VII, TF"
        },
        {
          "id": 297453,
          "text": "X, V, II, I"
        },
        {
          "id": 297454,
          "text": "VIII, IX, XI, XII"
        }
      ],
      "text": "Which factors are part of the intrinsic system of the coagulation cascade?",
      "unique_key": "Q8847147",
      "question_audio": null,
      "question_video": null,
      "map_id": 34783633,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) VIII, IX, XI, XII The intrinsic pathway of the coagulation cascade involves the following coagulation factors: Factor VIII, Factor IX, Factor XI, and Factor XII. These factors are activated in sequence to form a complex that eventually activates Factor X in the common pathway. The intrinsic pathway is triggered by damage to the blood vessel wall and is characterized by a cascade of enzyme activations that lead to the final step of clot formation. Reasons for Incorrect Options: A. II, VII, IX, X: This option is incorrect because Factor II (prothrombin) and Factor VII are not part of the intrinsic pathway. Factor II is part of the common pathway, and Factor VII is part of the extrinsic pathway (involved with tissue factor). B. VII, TF: This option refers to the extrinsic pathway of coagulation. Factor VII and tissue factor (TF) are key components of the extrinsic pathway, which is activated when tissue injury exposes TF. It is separate from the intrinsic pathway, making this option incorrect. C. X, V, II, I: These factors are all part of the common pathway of coagulation. Factor X, Factor V, Factor II (prothrombin), and Factor I (fibrinogen) are involved in the final steps of coagulation, leading to the conversion of fibrinogen to fibrin, but they do not belong to the intrinsic pathway.",
      "correct_choice_id": 297454,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/53401091700579164/53401091700579164.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/53401091700579164/53401091700579164.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97842,
      "choices": [
        {
          "id": 297455,
          "text": "Factor V inhibitor"
        },
        {
          "id": 297456,
          "text": "Factor X deficiency"
        },
        {
          "id": 297457,
          "text": "Factor VIII inhibitor"
        },
        {
          "id": 297458,
          "text": "Factor V deficiency"
        }
      ],
      "text": "Which coagulopathy is associated with amyloidosis?",
      "unique_key": "Q8000127",
      "question_audio": null,
      "question_video": null,
      "map_id": 34771490,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Factor X deficiency. Amyloidosis is a condition where amyloid proteins deposit abnormally in various tissues, leading to organ dysfunction. One of the coagulation abnormalities associated with amyloidosis is Factor X deficiency. The deposition of amyloid fibrils can bind to coagulation factors, particularly Factor X, leading to its inactivation or reduced activity. This deficiency in Factor X results in a bleeding tendency, as Factor X is essential in the common pathway of the coagulation cascade. This is the coagulopathy most commonly associated with amyloidosis. Reasons for Incorrect Options: A. Factor V inhibitor: Factor V inhibitors are rare and are typically associated with autoimmune conditions or specific hematologic disorders. Amyloidosis is not typically associated with Factor V inhibitors, so this option is incorrect. C. Factor VIII inhibitor: Factor VIII inhibitors are often seen in conditions like acquired hemophilia, which is not typically related to amyloidosis. Amyloidosis does not cause the production of inhibitors against Factor VIII, making this option incorrect. D. Factor V deficiency: Factor V deficiency is a rare inherited bleeding disorder, and while it can lead to bleeding tendencies, it is not associated with amyloidosis. There is no known direct link between amyloidosis and Factor V deficiency, so this option is incorrect.",
      "correct_choice_id": 297456,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/5555011700579174/5555011700579174.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/5555011700579174/5555011700579174.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97843,
      "choices": [
        {
          "id": 297459,
          "text": "Factor IX"
        },
        {
          "id": 297460,
          "text": "Factor XI"
        },
        {
          "id": 297461,
          "text": "Factor VII"
        },
        {
          "id": 297462,
          "text": "Factor I"
        }
      ],
      "text": "Which factor has the shortest plasma half-life?",
      "unique_key": "Q2559807",
      "question_audio": null,
      "question_video": null,
      "map_id": 34358290,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Factor VII. Factor VII has the shortest plasma half-life among the coagulation factors, typically around 4 to 6 hours. It is part of the extrinsic pathway and plays a crucial role in initiating coagulation by activating Factor X in the presence of tissue factor. Due to its relatively short half-life, Factor VII needs to be replenished more quickly than other factors in the coagulation cascade. This short half-life can be a consideration in treating bleeding disorders, as Factor VII may need to be re-administered more frequently in cases of deficiency or dysfunction. Reasons for Incorrect Options: A. Factor IX: Factor IX is part of the intrinsic pathway and has a much longer half-life than Factor VII. Its half-life is typically around 18 to 24 hours. Therefore, this option is incorrect. B. Factor XI: Factor XI, another factor of the intrinsic pathway, has a half-life that is longer than that of Factor VII. Its half-life is approximately 40 to 50 hours, making it longer than Factor VII's half-life, so this option is incorrect. D. Factor I: Factor I (fibrinogen) has a relatively long half-life of around 3 to 5 days. It is a stable protein that is produced in the liver and used in the final steps of coagulation to form the fibrin clot. Thus, it is not associated with a short half-life and is incorrect.",
      "correct_choice_id": 297461,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/65674321700579186/65674321700579186.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/65674321700579186/65674321700579186.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97844,
      "choices": [
        {
          "id": 297463,
          "text": "Solid tumors"
        },
        {
          "id": 297464,
          "text": "Aortic aneurysm"
        },
        {
          "id": 297465,
          "text": "Advanced lung cancer"
        },
        {
          "id": 297466,
          "text": "Sepsis/severe infection"
        }
      ],
      "text": "Which of the following conditions has the highest incidence of disseminated intravascular coagulation (DIC)?",
      "unique_key": "Q1782389",
      "question_audio": null,
      "question_video": null,
      "map_id": 34395486,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Sepsis/severe infection. Sepsis and severe infections are the most common triggers for disseminated intravascular coagulation (DIC). In sepsis, the systemic inflammatory response is triggered by the infection, leading to widespread activation of the coagulation cascade. This results in the formation of microthrombi in small blood vessels, leading to organ damage and consumption of clotting factors and platelets. As a result, patients with sepsis are at high risk for both clotting and bleeding complications, which is characteristic of DIC. Reasons for Incorrect Options: A. Solid tumors: While solid tumors can indeed be associated with DIC, particularly in the advanced stages or with the presence of tumor necrosis, the incidence is generally lower than that seen in sepsis. Tumor-related DIC is less common and usually occurs when the tumor is associated with infection, tissue destruction, or cytokine release. B. Aortic aneurysm: An aortic aneurysm can lead to complications such as hemorrhage or thromboembolism, but it is not a primary cause of DIC. DIC associated with aortic aneurysm is rare and typically occurs if there is significant tissue injury or infection, rather than being a direct result of the aneurysm itself. C. Advanced lung cancer: Advanced lung cancer can trigger DIC, particularly in the presence of infection, tumor necrosis, or other complications, but it is less commonly associated with DIC compared to sepsis. Although cancer-related DIC can occur, it is generally less frequent than DIC triggered by infection or sepsis.",
      "correct_choice_id": 297466,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/6735091700579196/6735091700579196.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/6735091700579196/6735091700579196.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97845,
      "choices": [
        {
          "id": 297467,
          "text": "A point mutation in Factor V"
        },
        {
          "id": 297468,
          "text": "An autoantibody to activated protein C"
        },
        {
          "id": 297469,
          "text": "A deletion in protein C"
        },
        {
          "id": 297470,
          "text": "A point mutation in protein C"
        }
      ],
      "text": "Activated protein C resistance due to Factor V Leiden is caused by which of the following?",
      "unique_key": "Q5756868",
      "question_audio": null,
      "question_video": null,
      "map_id": 34986240,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) A point mutation in Factor V",
      "correct_choice_id": 297467,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/16453501700579207/16453501700579207.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/16453501700579207/16453501700579207.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97846,
      "choices": [
        {
          "id": 297471,
          "text": "Erythrocytes"
        },
        {
          "id": 297472,
          "text": "Neutrophils"
        },
        {
          "id": 297473,
          "text": "Endothelial cells"
        },
        {
          "id": 297474,
          "text": "Monocytes"
        }
      ],
      "text": "Major source of von Willebrand factor",
      "unique_key": "Q3821917",
      "question_audio": null,
      "question_video": null,
      "map_id": 34185519,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Endothelial cells. The major source of von Willebrand factor (vWF) is the endothelial cells that line blood vessels. vWF is synthesized and stored in Weibel-Palade bodies within endothelial cells. It is released into the bloodstream upon vascular injury to facilitate platelet adhesion to the damaged vessel wall, playing a crucial role in primary hemostasis. Endothelial cells are the primary location for vWF production, and its release is vital in the coagulation process, particularly in conditions such as von Willebrand disease. Reasons for Incorrect Options: A. Erythrocytes: Erythrocytes (red blood cells) are not involved in the synthesis or storage of von Willebrand factor. They primarily function to carry oxygen throughout the body and do not play a significant role in the coagulation cascade. Therefore, this option is incorrect. B. Neutrophils: Neutrophils, a type of white blood cell involved in immune responses, do not produce or store von Willebrand factor. While neutrophils can release other substances during inflammation or infection, vWF is not one of them. This option is incorrect. D. Monocytes: Like neutrophils, monocytes are another type of white blood cell that participate in immune responses. However, they are not a major source of von Willebrand factor. This option is incorrect as vWF is not produced by monocytes.",
      "correct_choice_id": 297473,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25611851700579260/25611851700579260.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25611851700579260/25611851700579260.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97847,
      "choices": [
        {
          "id": 297475,
          "text": "VIII factor deficiency"
        },
        {
          "id": 297476,
          "text": "PTT increased"
        },
        {
          "id": 297477,
          "text": "PT increased"
        },
        {
          "id": 297478,
          "text": "Normal BT"
        }
      ],
      "text": "Hemophilia A has following except:",
      "unique_key": "Q8546539",
      "question_audio": null,
      "question_video": null,
      "map_id": 34060897,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) PT increased. Hemophilia A is a bleeding disorder caused by a deficiency in Factor VIII. It primarily affects the intrinsic pathway of the coagulation cascade. Since Factor VIII is involved in the activation of Factor X in the intrinsic pathway, the partial thromboplastin time (PTT) is prolonged in Hemophilia A due to impaired clotting. However, prothrombin time (PT), which assesses the extrinsic pathway (involving Factor VII), remains normal because Factor VII and the extrinsic pathway are unaffected by Factor VIII deficiency. Therefore, PT is not typically increased in Hemophilia A, making this the correct response. Reasons for Incorrect Options: A. VIII factor deficiency: This is the hallmark of Hemophilia A. It is caused by a deficiency in Factor VIII, which impairs the ability to form a clot in response to injury. This option correctly describes Hemophilia A and is not the exception. B. PTT increased: In Hemophilia A, the partial thromboplastin time (PTT) is increased because Factor VIII is crucial for the activation of Factor X in the intrinsic pathway. The deficiency in Factor VIII leads to delayed clot formation, which results in a prolonged PTT. This is a characteristic feature of Hemophilia A, making this option correct. D. Normal BT: Bleeding time (BT) is typically normal in Hemophilia A because the disorder affects clot formation (secondary hemostasis) rather than platelet function (primary hemostasis). Therefore, the platelets function normally in Hemophilia A, and the bleeding time is not prolonged. This option is correct and does not present an exception.",
      "correct_choice_id": 297477,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97848,
      "choices": [
        {
          "id": 297479,
          "text": "Idiopathic thrombocytopenic purpura"
        },
        {
          "id": 297480,
          "text": "Bernard-Soulier syndrome"
        },
        {
          "id": 297481,
          "text": "Disseminated intravascular coagulation"
        },
        {
          "id": 297482,
          "text": "Wiskott-Aldrich syndrome"
        }
      ],
      "text": "The presence of small sized platelets on the peripheral smear is characteristic of",
      "unique_key": "Q4089997",
      "question_audio": null,
      "question_video": null,
      "map_id": 34847200,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Wiskott-Aldrich syndrome. Wiskott-Aldrich syndrome is a rare X-linked immunodeficiency disorder that is characterized by a triad of thrombocytopenia, eczema, and recurrent infections. A key feature of this syndrome is the presence of small-sized platelets on the peripheral smear. The thrombocytopenia in Wiskott-Aldrich syndrome is associated with defective platelet production, leading to the production of abnormally small platelets, which are a hallmark of this condition. This characteristic helps differentiate Wiskott-Aldrich syndrome from other causes of thrombocytopenia. Reasons for Incorrect Options: A. Idiopathic thrombocytopenic purpura (ITP): ITP is an autoimmune disorder where antibodies target and destroy platelets, leading to thrombocytopenia. The peripheral smear in ITP typically shows normal-sized platelets, although there may be an increase in large platelets as a compensatory response to platelet destruction. However, small-sized platelets are not a defining characteristic of ITP, so this option is incorrect. B. Bernard-Soulier syndrome: Bernard-Soulier syndrome is a rare inherited platelet disorder characterized by giant platelets, not small platelets. This syndrome is caused by a defect in the platelet glycoprotein complex that is involved in platelet adhesion. The presence of giant platelets is a key feature on the peripheral smear, making this option incorrect. C. Disseminated intravascular coagulation (DIC): In DIC, the peripheral smear often shows fragmented red blood cells (schistocytes) and may also show thrombocytopenia. However, it does not typically feature small-sized platelets. In fact, platelets in DIC may appear normal in size or reduced in number due to consumption in the clotting process, but they are not characteristically small, making this option incorrect.",
      "correct_choice_id": 297482,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/31818481700579326/31818481700579326.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/31818481700579326/31818481700579326.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97849,
      "choices": [
        {
          "id": 297483,
          "text": "Ristocetin aggregation is normal"
        },
        {
          "id": 297484,
          "text": "Aggregation with collagen and ADP is normal"
        },
        {
          "id": 297485,
          "text": "Large platelets"
        },
        {
          "id": 297486,
          "text": "Thrombocytopenia"
        }
      ],
      "text": "Which is not true regarding Bernard – Soulier syndrome?",
      "unique_key": "Q3030308",
      "question_audio": null,
      "question_video": null,
      "map_id": 34715627,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Ristocetin aggregation is normal. Bernard-Soulier syndrome is an inherited platelet disorder caused by a defect in the platelet GPIb/IX/V complex, which is crucial for platelet adhesion to von Willebrand factor at the site of vascular injury. One of the key diagnostic features of Bernard-Soulier syndrome is abnormal ristocetin aggregation. Normally, ristocetin induces platelet aggregation by promoting the interaction between von Willebrand factor and the platelet GPIb receptor. In Bernard-Soulier syndrome, due to the defect in the GPIb receptor, ristocetin aggregation is abnormal or absent. Therefore, the statement that \"ristocetin aggregation is normal\" is not true, making this the correct response. Reasons for Incorrect Options: B. Aggregation with collagen and ADP is normal: In Bernard-Soulier syndrome, platelet aggregation responses to collagen and ADP are generally normal. The defect in this condition affects platelet adhesion (via GPIb), not platelet aggregation with other agonists like collagen and ADP. Therefore, this statement is true. C. Large platelets: Large platelets are a characteristic feature of Bernard-Soulier syndrome. Due to the defect in platelet production and the abnormal development of platelets, patients with this syndrome often have giant platelets on the peripheral smear. This is a diagnostic feature of the condition, making this statement true. D. Thrombocytopenia: Thrombocytopenia (low platelet count) is common in Bernard-Soulier syndrome because the abnormal platelets have a shortened lifespan and are cleared from circulation more rapidly. This is an expected feature of the condition, making this statement true.",
      "correct_choice_id": 297483,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/72937331700579340/72937331700579340.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/72937331700579340/72937331700579340.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97850,
      "choices": [
        {
          "id": 297487,
          "text": "Normal platelet count with prolonged bleeding time"
        },
        {
          "id": 297488,
          "text": "Thrombocytopenia with prolonged bleeding time"
        },
        {
          "id": 297489,
          "text": "Thrombocytosis with prolonged bleeding time"
        },
        {
          "id": 297490,
          "text": "Normal platelet count with normal bleeding time"
        }
      ],
      "text": "Which of the following statements about platelet function defects is true?",
      "unique_key": "Q6702182",
      "question_audio": null,
      "question_video": null,
      "map_id": 34486595,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Normal platelet count with prolonged bleeding time. Platelet function defects, such as in Bernard-Soulier syndrome, Glanzmann thrombasthenia, or von Willebrand disease, can result in prolonged bleeding time despite a normal platelet count. This is because the platelets, though present in normal numbers, do not function properly in terms of adhesion and aggregation, which are essential for effective clot formation. Thus, a prolonged bleeding time is observed in the absence of thrombocytopenia, which makes this statement true. Reasons for Incorrect Options: B. Thrombocytopenia with prolonged bleeding time: Thrombocytopenia (low platelet count) can cause prolonged bleeding time due to an insufficient number of platelets to form clots. However, this is not a specific feature of platelet function defects, but rather a feature of conditions such as idiopathic thrombocytopenic purpura (ITP) or other thrombocytopenic disorders. In platelet function defects, platelet count is usually normal, so this option is incorrect. C. Thrombocytosis with prolonged bleeding time: Thrombocytosis (an elevated platelet count) is typically not associated with prolonged bleeding time. In conditions of thrombocytosis, the bleeding time can be either normal or slightly prolonged due to increased platelet numbers, but not because of functional defects. Thrombocytosis does not usually lead to defective platelet function as seen in platelet function disorders. Therefore, this option is incorrect. D. Normal platelet count with normal bleeding time: This statement is not true for platelet function defects, as such defects are characterized by a prolonged bleeding time, even though the platelet count remains normal. A normal bleeding time would suggest that platelet function is intact, which is not the case in these disorders. This option is incorrect.",
      "correct_choice_id": 297487,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48460311700579356/48460311700579356.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48460311700579356/48460311700579356.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97851,
      "choices": [
        {
          "id": 297491,
          "text": "Fibrinogen decreased"
        },
        {
          "id": 297492,
          "text": "Thrombocytopenia"
        },
        {
          "id": 297493,
          "text": "Normal aPTT"
        },
        {
          "id": 297494,
          "text": "PT elevation"
        }
      ],
      "text": "In DIC, following are seen except",
      "unique_key": "Q3860849",
      "question_audio": null,
      "question_video": null,
      "map_id": 34716734,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Normal aPTT Disseminated intravascular coagulation (DIC) is a complex disorder characterized by widespread activation of the coagulation cascade, leading to both excessive clot formation and increased fibrinolysis. In DIC, there is consumption of clotting factors, leading to prolonged aPTT (activated partial thromboplastin time). This is due to the activation of the intrinsic and common pathways of the coagulation cascade. Therefore, a normal aPTT would not be expected in DIC, making option C incorrect. Reasons for Incorrect Options: A. Fibrinogen decreased: In DIC, fibrinogen levels are typically decreased because fibrinogen is consumed during the formation of microthrombi throughout the vascular system. The body uses up fibrinogen to form clots, which leads to a reduction in its levels. This statement is true and correctly describes a feature of DIC. B. Thrombocytopenia: Thrombocytopenia (low platelet count) is a hallmark of DIC. The widespread clotting consumes platelets in the formation of thrombi, leading to a decrease in the number of platelets available in circulation. This is a typical finding in DIC, making this option true. D. PT elevation: Prothrombin time (PT) is elevated in DIC due to the consumption of clotting factors, including Factors I, II, V, VII, and X, which are involved in the extrinsic and common pathways. This results in prolonged PT. An elevated PT is a common finding in DIC, so this statement is true.",
      "correct_choice_id": 297493,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24778691700579367/24778691700579367.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24778691700579367/24778691700579367.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97852,
      "choices": [
        {
          "id": 297495,
          "text": "Hemophilia B"
        },
        {
          "id": 297496,
          "text": "Thrombasthenia"
        },
        {
          "id": 297497,
          "text": "Afibrinogenemia"
        },
        {
          "id": 297498,
          "text": "Warfarin reversal"
        }
      ],
      "text": "Cryoprecipitate is useful in",
      "unique_key": "Q6249667",
      "question_audio": null,
      "question_video": null,
      "map_id": 34698732,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Afibrinogenemia Cryoprecipitate is a blood product that is rich in fibrinogen, factor VIII, von Willebrand factor, and factor XIII. It is used in conditions where there is a deficiency of fibrinogen, such as afibrinogenemia, a condition characterized by the absence of fibrinogen in the blood. Cryoprecipitate helps by providing the necessary fibrinogen to promote clotting and reduce bleeding in patients with this condition. Therefore, cryoprecipitate is particularly useful in treating afibrinogenemia, making this statement correct. Reasons for Incorrect Options: A. Hemophilia B: Hemophilia B is a deficiency of factor IX. The treatment for hemophilia B involves the administration of factor IX concentrates. Cryoprecipitate is not specifically used for treating hemophilia B, as it contains factor VIII, not factor IX. Therefore, this option is incorrect. B. Thrombasthenia: Thrombasthenia refers to a condition in which platelets are functionally abnormal, such as Glanzmann thrombasthenia. In this condition, platelet aggregation is impaired due to a defect in platelet receptors, and cryoprecipitate does not correct this defect. Thrombocytopenia or platelet function abnormalities are not typically treated with cryoprecipitate. Therefore, this option is incorrect. D. Warfarin reversal: To reverse the effects of warfarin, vitamin K or fresh frozen plasma (FFP) is usually administered to restore the vitamin K-dependent clotting factors (II, VII, IX, and X). Cryoprecipitate is not used for warfarin reversal, as it is not rich in the specific clotting factors required for this purpose. Therefore, this option is incorrect.",
      "correct_choice_id": 297497,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/67090971700579380/67090971700579380.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/67090971700579380/67090971700579380.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97853,
      "choices": [
        {
          "id": 297499,
          "text": "Delayed onset post trauma"
        },
        {
          "id": 297500,
          "text": "Sites affected are skin and mucous membranes"
        },
        {
          "id": 297501,
          "text": "Thrombocytopenia is a clinical example"
        },
        {
          "id": 297502,
          "text": "Deep tissues are usually not involved"
        }
      ],
      "text": "All of the following are features of primary hemostasis except",
      "unique_key": "Q1866698",
      "question_audio": null,
      "question_video": null,
      "map_id": 34898510,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Delayed onset post trauma. Primary hemostasis refers to the initial response to vascular injury, involving platelet adhesion, activation, and aggregation, along with the formation of a platelet plug. This process is usually immediate and occurs shortly after trauma, not with delayed onset. In contrast, secondary hemostasis (involving clotting factors) is typically the step that may have delayed onset after injury. Therefore, delayed onset does not characterize primary hemostasis, making option A the correct answer. Reasons for Incorrect Options: B. Sites affected are skin and mucous membranes: Primary hemostasis primarily affects the small blood vessels in areas such as the skin and mucous membranes. These areas are more vulnerable to minor injuries that cause bleeding, especially when there is a defect in platelet function or number. This feature is typical of primary hemostasis, making this statement correct. C. Thrombocytopenia is a clinical example: Thrombocytopenia, or a low platelet count, is a common cause of primary hemostasis defects. When platelets are deficient or not functioning properly, it leads to bleeding tendencies, particularly in the skin and mucous membranes, as seen in conditions like idiopathic thrombocytopenic purpura (ITP). Therefore, thrombocytopenia is indeed a clinical example of primary hemostasis issues, making this statement correct. D. Deep tissues are usually not involved: In primary hemostasis, the bleeding typically occurs in superficial tissues, such as the skin and mucous membranes, because small blood vessels are primarily involved. Deep tissues or internal bleeding are generally more associated with defects in secondary hemostasis, such as clotting factor deficiencies (e.g., hemophilia). Thus, deep tissues are usually not affected in primary hemostasis defects, making this statement correct.",
      "correct_choice_id": 297499,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48194761700579399/48194761700579399.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48194761700579399/48194761700579399.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97854,
      "choices": [
        {
          "id": 297503,
          "text": "Von Willebrand disease"
        },
        {
          "id": 297504,
          "text": "Factor XIII deficiency"
        },
        {
          "id": 297505,
          "text": "Lupus anticoagulant"
        },
        {
          "id": 297506,
          "text": "Vascular disorder of hemostasis"
        }
      ],
      "text": "PT and aPTT are normal in all of the following except",
      "unique_key": "Q6255399",
      "question_audio": null,
      "question_video": null,
      "map_id": 34246808,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Lupus anticoagulant Vwd shows prolonged aptt in severe cases when vwf is low enough to cause a functional deficiency in factor viii. However most cases show normal pt and aptt. Single best answer here is lupus anticoagulant as presence of this antibody prolongs aptt by inhibiting phospholipid used in the test (russell viper venom test : rvvt",
      "correct_choice_id": 297505,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/70371461700579415/70371461700579415.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/70371461700579415/70371461700579415.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97855,
      "choices": [
        {
          "id": 297507,
          "text": "Polycythemia vera"
        },
        {
          "id": 297508,
          "text": "Idiopathic myelofibrosis"
        },
        {
          "id": 297509,
          "text": "Chronic myeloid leukemia"
        },
        {
          "id": 297510,
          "text": "Essential thrombocytosis"
        }
      ],
      "text": "Most common cause of bleeding caused by platelet dysfunction in a myeloproliferative neoplasm is",
      "unique_key": "Q6934525",
      "question_audio": null,
      "question_video": null,
      "map_id": 34128478,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Polycythemia vera. In polycythemia vera (PV), a myeloproliferative disorder characterized by an increase in red blood cell mass, there is also an associated platelet dysfunction. Although PV typically presents with an elevated platelet count, the platelets are often functionally abnormal, leading to bleeding tendencies. This dysfunction can manifest as bleeding from mucous membranes, easy bruising, or epistaxis. Platelet dysfunction in PV is one of the most common causes of bleeding in myeloproliferative neoplasms due to the abnormal platelet aggregation and adhesion. Therefore, option A is the correct answer. Reasons for Incorrect Options: B. Idiopathic myelofibrosis: Idiopathic myelofibrosis (IMF) is another myeloproliferative disorder that can cause platelet dysfunction, but it is more commonly associated with thrombocytosis (elevated platelet count), rather than bleeding. In IMF, the bone marrow fibrosis leads to ineffective platelet production, and bleeding is less frequent than in PV. While IMF may cause platelet dysfunction, the bleeding complications are generally less prominent compared to polycythemia vera, making this option incorrect. C. Chronic myeloid leukemia: In chronic myeloid leukemia (CML), the primary defect is in the myeloid lineage, specifically due to the Philadelphia chromosome (BCR-ABL fusion gene), leading to overproduction of granulocytes. Bleeding is not typically associated with platelet dysfunction in CML. While CML can cause an elevated platelet count due to reactive processes, platelet dysfunction is not a prominent feature, and bleeding is less common. Therefore, this option is incorrect. D. Essential thrombocytosis: Essential thrombocytosis (ET) is characterized by an elevated platelet count, and while there can be a risk of thrombosis due to an excess of platelets, bleeding due to platelet dysfunction is also a well-recognized complication. However, it is not as commonly observed as in polycythemia vera, where platelet dysfunction is more pronounced. Therefore, although ET can cause bleeding, it is not the most common cause of bleeding in myeloproliferative neoplasms, making this option incorrect.",
      "correct_choice_id": 297507,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/41251051700579437/41251051700579437.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/41251051700579437/41251051700579437.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 97856,
      "choices": [
        {
          "id": 297511,
          "text": "Factor VIII assay"
        },
        {
          "id": 297512,
          "text": "Dilute Russell viper venom test"
        },
        {
          "id": 297513,
          "text": "Mixing studies"
        },
        {
          "id": 297514,
          "text": "Factor IX assay"
        }
      ],
      "text": "A male patient with history of bleeding was investigated and was found to have increased APTT but normal PT. His maternal uncle had a similar presentation. The next step of investigation should be",
      "unique_key": "Q2689465",
      "question_audio": null,
      "question_video": null,
      "map_id": 34415451,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Factor VIII assay. The patient's presentation, with increased activated partial thromboplastin time (APTT) and normal prothrombin time (PT), suggests a possible deficiency in an intrinsic pathway coagulation factor, as APTT primarily measures the intrinsic and common coagulation pathways. Additionally, the patient's family history of a similar bleeding tendency in his maternal uncle strongly points to an X-linked recessive inheritance, which is characteristic of Hemophilia A, a Factor VIII deficiency. To confirm this diagnosis, the next step would be to perform a Factor VIII assay to measure the actual level of Factor VIII in the patient's plasma. A deficiency in Factor VIII would be consistent with the diagnosis of Hemophilia A. Therefore, option A is the most appropriate next step in investigation. Reasons for Incorrect Options: B. Dilute Russell viper venom test: The dilute Russell viper venom test (DRVVT) is used to screen for lupus anticoagulant and antiphospholipid syndrome, which primarily affect the phospholipid-dependent coagulation pathway. This test is not useful for evaluating Factor VIII deficiency or Hemophilia A, as it does not specifically address intrinsic pathway factors. Therefore, this option is incorrect. C. Mixing studies: Mixing studies are performed when there is a prolonged APTT to determine if the prolongation is due to a factor deficiency or an inhibitor. While a mixing study could be considered, it is more appropriate when there is suspicion of an inhibitor, such as in lupus anticoagulant or a Factor VIII inhibitor. However, in this case, the family history of similar bleeding tendencies points more directly to Hemophilia A, making a Factor VIII assay a more focused next step. Therefore, this option is less appropriate than a direct Factor VIII assay. D. Factor IX assay: A Factor IX assay would be performed if there were suspicion of Hemophilia B, which is caused by a Factor IX deficiency. However, Hemophilia B is less likely given the family history of a maternal uncle with a similar bleeding presentation, which is more characteristic of Hemophilia A (due to Factor VIII deficiency). Therefore, this option is incorrect.",
      "correct_choice_id": 297511,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/61381131700579511/61381131700579511.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/61381131700579511/61381131700579511.m3u8",
      "question_images": [],
      "explanation_images": []
    }
  ]
}